# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0206 |
| Population Package | PP-0206 |
| Title | Neoadjuvant Therapy |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Source Basis | Project Source Files |
| Decision Status | Approved / Locked |

---

# QA Gate Summary

| QA Layer | Result |
|---|---|
| Layer 1 — Content QA | PASS |
| Layer 2 — Clinical QA | PASS |
| Layer 3 — Educational QA | PASS |
| Layer 4 — Governance QA | PASS |
| Evidence Traceability | PASS |
| Boundary Integrity | PASS |
| Knowledge Graph Integrity | PASS |
| Gold Depth Integrity | PASS |
| Package Integrity | PASS |

---

# Layer 1 — Content QA

## Single Educational Question

The package answers:

> **What is neoadjuvant therapy in gastric cancer, why may treatment be given before definitive surgery, how does it fit within the overall treatment sequence, and how are response, resectability, tumor biology, and patient fitness integrated into this strategy?**

**PASS**

---

## Scope Respected

The package remains focused on:

- treatment before surgery;
- clinical rationale;
- treatment sequencing;
- response/reassessment;
- relationship to surgery;
- selected MSI-H/dMMR immunotherapy.

**PASS**

---

## No Hidden Second Package

The package does not become:

- a FLOT package;
- a perioperative chemotherapy package;
- an adjuvant package;
- an immunotherapy drug package;
- a biomarker-testing package;
- a surgery package;
- a response-assessment package;
- a recurrence package.

**PASS**

---

## Clinical Knowledge Blocks Complete

The CKO includes:

- definition;
- rationale;
- terminology;
- staging/resectability;
- evidence;
- treatment sequencing;
- response;
- surgery interface;
- patient-facing explanations;
- misconceptions;
- key messages;
- runtime safety rules;
- Knowledge Graph;
- Boundary;
- revision history.

**PASS**

---

## Patient-Facing Depth

The package includes:

- definition in plain language;
- “why before surgery?” explanation;
- distinction from perioperative/adjuvant therapy;
- patient questions;
- misconceptions;
- response interpretation;
- uncertainty;
- safety-oriented language.

**PASS**

---

# Layer 2 — Clinical QA

## Definition

“Neoadjuvant therapy” is correctly defined as treatment before definitive surgery.

**PASS**

Source basis:

NCI patient-facing Treatment of Stomach Cancer.

---

## Neoadjuvant vs Perioperative

The package correctly distinguishes:

- neoadjuvant/preoperative = before surgery;
- adjuvant = after surgery;
- perioperative = before + after surgery.

**PASS**

---

## Neoadjuvant vs FLOT

FLOT is correctly represented as a regimen rather than a synonym for neoadjuvant therapy.

**PASS**

---

## Neoadjuvant vs Unresectable Disease

The package does not equate treatment before surgery with unresectability.

**PASS**

---

## Stage Dependence

The package correctly states that treatment sequencing is stage- and resectability-dependent.

**PASS**

---

## Early Gastric Cancer

The package correctly preserves the NCCN distinction that Tis/T1a tumors may follow endoscopic-resection pathways.

**PASS**

---

## Resectable T2+

The package correctly represents current NCCN positioning of perioperative systemic therapy for appropriate resectable T2+ disease.

**PASS**

---

## MSI-H/dMMR

The package correctly treats MSI-H/dMMR as a selected subgroup for neoadjuvant/perioperative immunotherapy.

**PASS**

---

## Universal Immunotherapy Avoidance

No statement generalizes neoadjuvant immunotherapy to all gastric cancers.

**PASS**

---

## NEONIPIGA

The package correctly identifies:

- phase II;
- 32 patients;
- locally advanced gastric/EGJ adenocarcinoma;
- confirmed MSI-H/dMMR;
- nivolumab + ipilimumab;
- subsequent nivolumab;
- 29 R0 resections;
- approximately 59% pathologic CR.

**PASS**

---

## Pembrolizumab Evidence

The package correctly notes:

- 35 locally advanced MSI-H/dMMR solid tumors;
- most stage III colorectal cancer;
- ORR 82%;
- CR 30%;
- 17 resected;
- 65% pathologic CR.

It explicitly avoids presenting this as a gastric-specific randomized result.

**PASS**

---

## MAGIC

The package correctly represents:

- perioperative rather than pure neoadjuvant design;
- stage II+ gastric/lower-third esophageal adenocarcinoma;
- ECF before and after surgery;
- surgery-alone comparator;
- PFS HR 0.66;
- OS HR 0.75;
- 5-year OS 36.3% vs 23%.

**PASS**

---

## FLOT4

The package correctly represents:

- 716 patients;
- stage IB–III;
- resectable gastric/GEJ adenocarcinoma;
- perioperative FLOT vs ECF/ECX;
- median OS 50 vs 35 months;
- HR 0.77;
- margin-free resection 85% vs 78%.

**PASS**

---

## Response Assessment

The package correctly describes response assessment as part of the post-preoperative-treatment pathway.

It does not invent a universal response protocol.

**PASS**

---

## Complete Response After Neoadjuvant Immunotherapy

The package preserves NCCN uncertainty regarding the role of surgery after biopsy-proven and radiologic/metabolic complete response in selected MSI-H/dMMR disease.

**PASS**

---

## Pathologic Response

The package correctly states that pathologic response/histologic tumor regression can have prognostic relevance.

It does not equate pathologic response with cure.

**PASS**

---

## Individualized Prescription

No individualized treatment is prescribed.

**PASS**

---

# Layer 2A — Numerical Integrity

| Claim | Verification |
|---|---|
| MAGIC PFS HR 0.66 | PASS |
| MAGIC OS HR 0.75 | PASS |
| MAGIC 5-year OS 36.3% vs 23% | PASS |
| FLOT4 n=716 | PASS |
| FLOT4 median OS 50 vs 35 months | PASS |
| FLOT4 HR 0.77 | PASS |
| FLOT4 margin-free resection 85% vs 78% | PASS |
| NEONIPIGA n=32 | PASS |
| NEONIPIGA R0 resection n=29 | PASS |
| NEONIPIGA ~59% pCR | PASS |
| Pembrolizumab ORR 82% | PASS |
| Pembrolizumab CR 30% | PASS |
| Pembrolizumab resected n=17 | PASS |
| Pembrolizumab pCR 65% | PASS |

---

# Layer 2B — Evidence Interpretation QA

## Historical vs Current

Historical trial evidence is distinguished from current guideline positioning.

**PASS**

## Randomized vs Phase II

MAGIC/FLOT4 are not represented as equivalent to NEONIPIGA.

**PASS**

## Gastric-Specific vs Mixed Population

The pembrolizumab solid-tumor study is explicitly qualified as mostly colorectal.

**PASS**

## Population-Level vs Individual

Trial results are not converted into individual predictions.

**PASS**

---

# Layer 3 — Educational QA

## Plain Language

Technical concepts are explained before or while being used.

**PASS**

## Terminology

The package explains:

- neoadjuvant;
- perioperative;
- adjuvant;
- resectable;
- MSI-H;
- dMMR;
- pathologic complete response;
- resectability;
- restaging.

**PASS**

## Logical Flow

The educational progression is:

**What is it?**

↓

**Why use it?**

↓

**Who may receive it?**

↓

**What evidence supports it?**

↓

**What happens after treatment?**

↓

**How does response affect the pathway?**

↓

**How does it connect to surgery/postoperative therapy?**

**PASS**

---

# Layer 3A — Patient Safety QA

## False Reassurance

No statement says:

- complete response guarantees cure;
- neoadjuvant therapy guarantees surgery;
- shrinkage guarantees successful treatment.

**PASS**

## False Alarm

No statement says:

- neoadjuvant therapy means metastatic disease;
- lack of shrinkage automatically means treatment failure.

**PASS**

## Treatment Instructions

No individualized dose, cycle, or treatment-switch instructions.

**PASS**

## Immunotherapy Safety

No universal immunotherapy recommendation.

**PASS**

---

# Layer 3B — Misconception QA

| Misconception | Addressed |
|---|---|
| Neoadjuvant = unresectable | PASS |
| Neoadjuvant = chemotherapy | PASS |
| Neoadjuvant = FLOT | PASS |
| Everyone needs preoperative treatment | PASS |
| Complete response = no surgery | PASS |
| Complete response = cure | PASS |
| No shrinkage = failure | PASS |
| MSI-H/dMMR = everyone gets immunotherapy | PASS |
| Treatment before surgery is unnecessary delay | PASS |
| Preoperative treatment guarantees easier surgery | PASS |

---

# Layer 4 — Governance QA

## Source-First

Relevant project Source Files were searched before production.

**PASS**

The source set included:

- NCCN Gastric Cancer v2.2026;
- NCI Gastric Cancer Treatment PDQ;
- NCI Treatment of Stomach Cancer;
- ACS Chemotherapy for Stomach Cancer;
- ACS Immunotherapy for Stomach Cancer;
- ESMO-ASCO 2023;
- Gold governance/specification;
- approved Discussion Batch example;
- approved completed Gold artifact examples.

**PASS**

---

## Approved Decision Batch

PP-0206 Decision Batch was approved and locked by the Project Coordinator before production.

**PASS**

---

## Exact PP Identity

PP-0206 is:

> **Neoadjuvant Therapy**

The Project Coordinator explicitly updated the registry accordingly.

**PASS**

---

## Gold Structure

Required artifacts:

1. 01_CKO.md
2. 02_KNOWLEDGE_PASSPORT.md
3. 03_PRIMARY_EVIDENCE_PACKAGE.md
4. 04_QA_REPORT.md

**PASS**

---

## Gold Depth

The artifacts preserve the established Gold structure and deep clinical reasoning standard.

They are not intentionally compressed into summaries.

**PASS**

---

# Knowledge Graph QA

## Prerequisite

- staging;
- treatment overview;
- surgical context;
- biomarker context.

**PASS**

## Related

- PP-0203 Perioperative Chemotherapy;
- PP-0204 FLOT;
- PP-0205 Adjuvant Therapy;
- biomarker PPs;
- immunotherapy PPs;
- response PPs.

**PASS**

## Downstream

- response assessment;
- surgical evaluation;
- surgery;
- postoperative therapy;
- surveillance;
- alternative advanced/recurrent pathway.

**PASS**

---

# Adjacent Package Overlap QA

## PP-0203 — Perioperative Chemotherapy

PP-0206:

> preoperative treatment concept.

PP-0203:

> complete perioperative chemotherapy strategy.

**PASS**

---

## PP-0204 — FLOT

PP-0206:

> FLOT as an example of a regimen that can form the preoperative component of perioperative therapy.

PP-0204:

> FLOT regimen ownership.

**PASS**

---

## PP-0205 — Adjuvant Therapy

PP-0206:

> before surgery.

PP-0205:

> after surgery.

**PASS**

---

## PP-0195–0201 — Surgical PPs

PP-0206:

> treatment-to-surgery relationship.

Surgical PPs:

> operative treatment.

**PASS**

---

## Biomarker Testing

PP-0206:

> selected biomarker-defined treatment pathway.

Biomarker PPs:

> testing and interpretation.

**PASS**

---

## Immunotherapy

PP-0206:

> selected neoadjuvant immunotherapy concept.

Immunotherapy PPs:

> detailed treatment.

**PASS**

---

## Response Assessment

PP-0206:

> need for reassessment.

Response PPs:

> formal response methodology.

**PASS**

---

# Boundary QA

**Core =** neoadjuvant/preoperative treatment strategy; rationale; treatment-before-surgery concept; relationship to staging/resectability; selected neoadjuvant immunotherapy; response and surgical-transition concepts; patient-facing explanation.

**Supporting =** MAGIC; FLOT4; MSI-H/dMMR evidence; pathologic response; restaging; multidisciplinary treatment planning.

**Explicitly Excluded =** regimen-level chemotherapy; FLOT details; complete perioperative chemotherapy; adjuvant therapy; detailed immunotherapy; biomarker testing; surgery/lymphadenectomy technique; formal response methodology; individualized prescription; recurrent/metastatic management.

**Delegated-to PP =** PP-0203, PP-0204, PP-0205, PP-0195–0201, PP-0191, biomarker-testing PPs, immunotherapy PPs, response/imaging PPs, downstream treatment PPs.

**PASS**

---

# Source Traceability QA

## NCCN v2.2026

Supports:

- treatment pathway;
- perioperative systemic therapy;
- MSI-H/dMMR neoadjuvant/perioperative immunotherapy;
- response assessment;
- uncertainty after complete response;
- multidisciplinary management.

**PASS**

## NCI PDQ

Supports:

- MAGIC;
- FLOT4;
- randomized evidence interpretation.

**PASS**

## NCI Patient-Facing Treatment

Supports:

- definition of neoadjuvant/preoperative therapy;
- perioperative terminology;
- adjuvant distinction.

**PASS**

## ACS Chemotherapy

Supports:

- staging before surgery;
- preoperative treatment;
- perioperative treatment;
- MSI-H/dMMR pathway.

**PASS**

## ESMO-ASCO

Supports:

- multidisciplinary treatment sequencing;
- patient treatment planning.

**PASS**

---

# Overclaim Prevention QA

## Claim

“Neoadjuvant therapy cures cancer.”

**Rejected.**

Correct framing:

> It is part of a treatment strategy intended to improve disease control and treatment outcomes.

**PASS**

---

## Claim

“Everyone with gastric cancer should receive treatment before surgery.”

**Rejected.**

**PASS**

---

## Claim

“FLOT is neoadjuvant therapy.”

**Rejected as definition.**

Correct:

> FLOT is a regimen that can be used in the preoperative component of perioperative therapy.

**PASS**

---

## Claim

“Complete response means surgery is unnecessary.”

**Rejected.**

**PASS**

---

## Claim

“MSI-H/dMMR means immunotherapy is mandatory.”

**Rejected.**

**PASS**

---

## Claim

“No response means treatment failed.”

**Rejected.**

**PASS**

---

## Claim

“MAGIC proves the preoperative component alone caused the survival benefit.”

**Rejected.**

The trial evaluated perioperative chemotherapy.

**PASS**

---

## Claim

“FLOT4 proves FLOT before surgery alone improves survival.”

**Rejected.**

FLOT4 evaluated perioperative FLOT.

**PASS**

---

# Gold Artifact Completeness Check

| Artifact | Present | Structural QA | Depth QA |
|---|---|---|---|
| 01_CKO.md | PASS | PASS | PASS |
| 02_KNOWLEDGE_PASSPORT.md | PASS | PASS | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | PASS | PASS | PASS |
| 04_QA_REPORT.md | PASS | PASS | PASS |

---

# Package Integrity

## Required File 1

`01_CKO.md`

**PASS**

## Required File 2

`02_KNOWLEDGE_PASSPORT.md`

**PASS**

## Required File 3

`03_PRIMARY_EVIDENCE_PACKAGE.md`

**PASS**

## Required File 4

`04_QA_REPORT.md`

**PASS**

## ZIP Package

`PP-0206_Neoadjuvant_Therapy_GOLD_v1.0.0.zip`

**PASS**

---

# Final Clinical Integrity Decision

The package is:

- atomic;
- patient-centered;
- source-grounded;
- clinically governed;
- evidence-traceable;
- strategy-level;
- non-prescriptive;
- boundary-controlled;
- Knowledge-Graph connected;
- compatible with adjacent PPs;
- maintainable.

**PASS**

---

# Final Quality Decision

## Overall

**PASS**

## Gold

**GOLD**

## Integration

**READY FOR INTEGRATION**

# QA Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
